CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).

Anne M. Noonan,Jacob S. Yount,Jason J. David,Mindy Hoang,Colin W. Stets,Tanios Bekaii-Saab,Ying Huang,Wendy L. Frankel,Cynthia Timmers,John L. Hays,James L. Chen

CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).

2020

Anne M. Noonan
Jacob S. Yount
Jason J. David
Mindy Hoang
Colin W. Stets
Tanios Bekaii-Saab
Ying Huang
Wendy L. Frankel
Cynthia Timmers
John L. Hays
James L. Chen

746Background: Pelareorep is a proprietary formulation of live, replication-competent, naturally occurring Reovirus Type 3 Dearing strain. A randomized phase II trial of pelareorep in combination w...

Keywords:

Adenocarcinoma
Cancer research
Medicine
Pathology
Biomarker (medicine)
Reovirus type 3

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations